HUCHMED的肺癌治疗组合在中国获得了快速审查,为抗药性病例提供了新的希望。 HUTCHMED's lung cancer treatment combo gains fast-track review in China, offering new hope for resistant cases.

HHUCHMED在中国获得优先审查地位,以申请将ORPATHYSZ和TAGRISSOZ结合使用,治疗那些在最初的EGFR抑制剂治疗后发现其疾病进展的肺癌病人的MET放大作用。 HUTCHMED has received priority review status in China for its application to use a combination of ORPATHYS® and TAGRISSO® to treat lung cancer patients with MET amplification who have seen their disease progress after initial EGFR inhibitor treatment. 该应用程序得到第三阶段试验的支持,试验表明组合能够解决EGFR抑制剂的抗药性。 The application is backed by a Phase III trial showing the combination can tackle EGFR inhibitor resistance. 这标志着首次对这种药物组合进行监管申报,为这些病人提供继续口服治疗的希望。 This marks the first regulatory filing for this drug combination, offering hope for a continued oral treatment option for these patients.